LY3885125 + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias, Non-Alcoholic Fatty Liver Disease
Trial Timeline
Aug 10, 2023 → Feb 12, 2025
NCT ID
NCT06007651About LY3885125 + Placebo
LY3885125 + Placebo is a phase 1 stage product being developed by Eli Lilly for Dyslipidemias. The current trial status is terminated. This product is registered under clinical trial identifier NCT06007651. Target conditions include Dyslipidemias, Non-Alcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06007651 | Phase 1 | Terminated |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 33 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 85 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 52 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 51 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 49 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 30 |